Robert G. McNeil, Ph.D. Managing Director
Robert McNeil has over thirty six years of experience as an active investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979 and has served since then as a Managing Director of Sanderling’s seven investment partnerships.
Dr. McNeil has been the seed investor for many successful companies including Western Technology Ventures, Advanced Cardiovascular Systems (acquired by Eil Lilly and spun out as Guidant Corp.) and Ventritex (acquired by St. Jude Medical). Dr. McNeil was a founder, Chairman and Director of CoMentis, and the Chairman of Ista Pharmaceuticals, GeminX, as well as other entities. Currently he serves as CEO of DalCor Pharmaceuticals, U.K and is active in Sanderling VII portfolio companies.
As an active investor, Dr. McNeil has been instrumental in the development many companies. In addition he has been instrumental in the development and management of Sanderling Ventures six successive partnerships. In each case, close relationships with management and careful understanding of the companies’ technologies have allowed successful development of products at very early stage.
Dr. McNeil earned his Ph.D. in the fields of molecular biology, biochemistry and genetics in 1972 from the University of California, Irvine. He is well known for his love of the sea and restoration of important historical vessels.